X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs NATCO PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA NATCO PHARMA AJANTA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 18.5 23.1 80.3% View Chart
P/BV x 7.4 17.5 42.4% View Chart
Dividend Yield % 0.8 0.7 123.8%  

Financials

 AJANTA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
NATCO PHARMA
Mar-14
AJANTA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,720877 196.1%   
Low Rs1,103424 260.4%   
Sales per share (Unadj.) Rs194.6223.4 87.1%  
Earnings per share (Unadj.) Rs45.231.1 145.6%  
Cash flow per share (Unadj.) Rs50.340.3 124.9%  
Dividends per share (Unadj.) Rs8.005.00 160.0%  
Dividend yield (eoy) %0.60.8 73.7%  
Book value per share (Unadj.) Rs132.0219.5 60.2%  
Shares outstanding (eoy) m88.7733.07 268.4%   
Bonus/Rights/Conversions -PA-  
Price / Sales ratio x7.32.9 249.2%   
Avg P/E ratio x31.220.9 149.1%  
P/CF ratio (eoy) x28.116.1 173.8%  
Price / Book Value ratio x10.73.0 360.9%  
Dividend payout %17.716.1 109.9%   
Avg Mkt Cap Rs m125,29921,504 582.7%   
No. of employees `000NANA-   
Total wages/salary Rs m2,5701,128 227.9%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,2757,389 233.8%  
Other income Rs m166167 99.5%   
Total revenues Rs m17,4427,556 230.8%   
Gross profit Rs m5,8071,793 323.8%  
Depreciation Rs m451304 148.0%   
Interest Rs m49366 13.4%   
Profit before tax Rs m5,4741,290 424.4%   
Minority Interest Rs m046 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460309 472.9%   
Profit after tax Rs m4,0141,027 390.7%  
Gross profit margin %33.624.3 138.5%  
Effective tax rate %26.723.9 111.4%   
Net profit margin %23.213.9 167.1%  
BALANCE SHEET DATA
Current assets Rs m7,6393,681 207.5%   
Current liabilities Rs m2,7153,123 86.9%   
Net working cap to sales %28.57.6 377.1%  
Current ratio x2.81.2 238.7%  
Inventory Days Days4389 48.3%  
Debtors Days Days7959 134.1%  
Net fixed assets Rs m6,9147,685 90.0%   
Share capital Rs m177331 53.5%   
"Free" reserves Rs m11,4426,670 171.5%   
Net worth Rs m11,7217,259 161.5%   
Long term debt Rs m149955 15.6%   
Total assets Rs m14,81411,957 123.9%  
Interest coverage x112.94.5 2,497.6%   
Debt to equity ratio x00.1 9.6%  
Sales to assets ratio x1.20.6 188.7%   
Return on assets %27.411.7 235.3%  
Return on equity %34.214.2 242.0%  
Return on capital %46.520.7 224.5%  
Exports to sales %55.139.4 140.1%   
Imports to sales %6.05.7 105.4%   
Exports (fob) Rs m9,5272,908 327.6%   
Imports (cif) Rs m1,038421 246.3%   
Fx inflow Rs m10,4223,445 302.5%   
Fx outflow Rs m1,678703 238.8%   
Net fx Rs m8,7442,743 318.8%   
CASH FLOW
From Operations Rs m3,2641,440 226.6%  
From Investments Rs m-2,093-1,089 192.2%  
From Financial Activity Rs m-1,186-353 336.2%  
Net Cashflow Rs m-15-1 993.3%  

Share Holding

Indian Promoters % 73.8 52.0 141.8%  
Foreign collaborators % 0.0 1.5 -  
Indian inst/Mut Fund % 1.6 7.8 19.8%  
FIIs % 7.6 16.6 45.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 26.0 65.4%  
Shareholders   20,968 25,395 82.6%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  IPCA LABS  JUBILANT LIFE SCIENCES  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Extends Losses; Pharma Stocks Top Losers(Closing)

After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


May 21, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - IPCA LABS COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS